Ethyl Pyruvate Combats Human Leukemia Cells but Spares Normal Blood Cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 27579985.
- Also identified by DOI 10.1371/journal.pone.0161571 and PMC identifier 5006986.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Ethyl pyruvate, a known ROS scavenger and anti-inflammatory drug was found to combat leukemia cells. Tumor cell killing was achieved by concerted action of necrosis/apoptosis induction, ATP depletion, and inhibition of glycolytic and para-glycolytic enzymes. Ethyl lactate was less harmful to leukemia cells but was found to arrest cell cycle in the G0/G1 phase. Both, ethyl pyruvate and ethyl lactate were identified as new inhibitors of GSK-3β. Despite the strong effect of ethyl pyruvate on leukemia cells, human cognate blood cells were only marginally affected. The data were compiled by immune blotting, flow cytometry, enzyme activity assay and gene array analysis. Our results inform new mechanisms of ethyl pyruvate-induced cell death, offering thereby a new treatment regime with a high therapeutic window for leukemic tumors.
Medical subject headings
- Adenosine Triphosphate
- Free Radical Scavengers
- G1 Phase Cell Cycle Checkpoints
- Leukemia
- Pyruvates